Wandercraft Acquires Ekso Bionics to Scale Medical Exoskeleton Platform
What happened On 1 October 2026, Paris-based robotics company Wandercraft said it had acquired Ekso Bionics, Inc. from a subsidiary of ChronoScale Holdings Corporation. Both boards unanimously approved the transaction, which was signed and closed at the same time. Financial terms were not disclosed. Wandercraft framed the combination as a leading medical exoskeleton platform with […]
Fresenius Takes Full Ownership of mAbxience Biosimilars Platform
Fresenius has closed the buyout of the minority stake in mAbxience, turning a four-year majority partnership into a fully owned biosimilars and biologics manufacturing platform inside Fresenius Kabi. For hospital buyers, payers, and rival CDMO and biosimilar developers, the move is less about a fresh entry and more about who controls capacity, launch timing, and […]
Leica Biosystems Closes StatLab Deal to Widen Pathology Stack
What happened Leica Biosystems, a Danaher company focused on anatomic and digital pathology for cancer diagnostics, has completed its acquisition of StatLab Medical Products. The close was announced on 28 September 2026. StatLab, previously owned by Linden Capital Partners and Audax Private Equity, supplies pre-analytical consumables and equipment that laboratories use before staining, imaging, and […]
Sun Pharma Licenses LIB Lerodalcibep Outside US and China
Sun Pharmaceutical Industries is buying distribution and manufacturing scale for a next-wave cholesterol biologic rather than waiting to invent one. On 28 September 2026 the company said it and its subsidiaries signed an exclusive licensing, commercialisation and manufacturing agreement with LIB Therapeutics Inc for lerodalcibep, covering every market except the United States and China. What […]
Grunenthal to Buy Bayer Stivarga for Up to EUR 375 Million
German specialty pharma group Grunenthal has agreed to acquire Bayer’s cancer medicine Stivarga (regorafenib) for up to EUR 375 million, adding an established oral oncology asset that is already approved in more than 90 markets. For buyers and sellers of mature specialty brands, the deal is a clean read on how late-lifecycle oncology products are […]
Telix Agrees 1.65 Billion Merger with German Isotope Leader ITM
Telix Pharmaceuticals has signed a strategic agreement to merge with Munich-based ITM Isotope Technologies, a scaled producer of therapeutic radioisotopes and a developer of targeted radionuclide therapies. The deal puts an upfront enterprise value of about US$1.65 billion on ITM on a cash-free and debt-free basis, with up to US$700 million more tied to regulatory […]
LEO Pharma Closes Dersimelagon Deal as FDA Grants Priority Review
LEO Pharma moved a rare-dermatology asset from deal closing into a near-term regulatory window in one day. On 18 September 2026 the Danish medical-dermatology specialist said the U.S. Food and Drug Administration accepted the New Drug Application for dersimelagon, granted Priority Review, and set a Prescription Drug User Fee Act action date by the end […]
GSK Buys Chimagen Trispecific TCE to Deepen Myeloma Franchise
GSK has locked full global rights to a trispecific T-cell engager from privately held Chimagen Biosciences for multiple myeloma. The London-listed biopharma plans to develop and commercialise the asset, with first-in-human work eyed for 2027, under a package that can reach up to $750 million in upfront and success-based milestones. The move builds on an […]
FDA Clears Telix Pixclara as First FET-PET Glioma Drug
US neuro-oncology imaging just crossed a regulatory line that European practice guidelines already assumed. On 14 September 2026, Telix Pharmaceuticals said the US Food and Drug Administration approved Pixclara (floretyrosine F 18, or 18F-FET), making it the first FDA-cleared FET-PET imaging drug for glioma. The label is narrow and consequential: help differentiate recurrent or progressive […]
Axogen Buys BioCircuit NerveTape to Scale Sutureless Nerve Repair
Axogen is paying cash for a sutureless nerve-repair device that lowers the skill barrier in microsurgery, a bet that commercial reach now matters as much as graft science in peripheral nerve care. What happened On 10 September 2026, Axogen Inc. said it had signed a definitive agreement to acquire BioCircuit Technologies Inc., the Atlanta developer […]